Biogen Idec (NQ:BIIB)

218.59 -1.29 (-0.59%)

Delayed Quote Updated: 12:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

62 63 Next >

3 Biotech Moonshots to Bet on the Future of Health ↗

November 06, 2023

Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk.

Via InvestorPlace

Topics Intellectual Property

Looking Into Biogen's Recent Short Interest ↗

November 06, 2023

Via Benzinga

Biogen Appoints Monish Patolawala to its Board of Directors

November 06, 2023

Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformation

From Biogen Inc.

Via GlobeNewswire

Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years ↗

November 01, 2023

Via Benzinga

Assessing Biogen's Performance Against Competitors In Biotechnology Industry ↗

October 30, 2023

Via Benzinga

$1000 Invested In Biogen 20 Years Ago Would Be Worth This Much Today ↗

October 18, 2023

Via Benzinga

Inquiry Into Biogen's Competitor Dynamics In Biotechnology Industry ↗

October 16, 2023

Via Benzinga

BIIB Stock Price Analysis: To Bet Or To Fold The Cards ↗

October 14, 2023

Massachusetts-based Biogen (BIIB) is a global biotechnology leader, researching and developing therapies for debilitating diseases impacting the central nervous system.

Via Talk Markets

Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment ↗

October 26, 2023

Both companies are working on under-the-skin injections for Alzheimer's treatment.

Via Investor's Business Daily

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On

October 25, 2023

From Biogen Inc.

Via GlobeNewswire

Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease ↗

October 25, 2023

Biogen Inc. (NASDAQ: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau,

Via Benzinga

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

October 25, 2023

From Biogen Inc.

Via GlobeNewswire

Analyst Ratings for Biogen ↗

October 11, 2023

Via Benzinga

An Oversold Small Cap Industrial That Insiders Are Buying Ahead Of Earnings This Week ↗

October 24, 2023

Another RSI Buy In a post last month, we wrote about the power of RSI (Relative Strength Index) as a technical indicator (Relative Strength Index) in relation to Stitch Fix, Inc. (NASDAQ: SFIX)

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 23, 2023

Via Benzinga

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

October 19, 2023

From Biogen Inc.

Via GlobeNewswire

3 Struggling Stocks Investors Shouldn't Buy on the Dip ↗

October 18, 2023

These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better.

Via The Motley Fool

$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,800 Today ↗

October 03, 2023

Via Benzinga

Is Biogen Stock a Buy Now? ↗

September 28, 2023

It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.

Via The Motley Fool

Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage ↗

October 13, 2023

The U.S.

Via Benzinga

7 Low-Volatility Stocks to Buy if You’re a Concerned Investor ↗

October 11, 2023

With market and economic conditions worrying many investors, it may be time to consider the virtues of low-volatility stocks.

Via InvestorPlace

Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready ↗

October 11, 2023

Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are...

Via Benzinga

LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly ↗

October 10, 2023

Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC: ESALY)/ Biogen Inc's (NASDAQ:

Via Benzinga

Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio ↗

October 07, 2023

Jiangsu QYuns Therapeutics filed for a Hong Kong IPO to underwrite development of its portfolio of clinical stage biologic antibody drugs for autoimmune and allergic diseases. Meanwhile, Biogen...

Via Talk Markets

Topics Initial Public Offering

Biotech Sector: On The Verge Of Triumph Or Turmoil? ↗

October 06, 2023

In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.

Via Talk Markets

An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8 ↗

October 05, 2023

Paying Attention To Gold Miners On Zero Hedge on Monday, contributing editor “Quoth The Raven” suggested “paying urgent attention to gold miners”:

Via Benzinga

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

September 29, 2023

From Biogen Inc.

Via GlobeNewswire

Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder ↗

September 26, 2023

IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.

Via Investor's Business Daily

Biogen Completes Acquisition of Reata Pharmaceuticals

September 26, 2023

From Biogen Inc.

Via GlobeNewswire

Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories ↗

September 25, 2023

Benzinga

Via Benzinga

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

62 63 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.